Abbott LaboratoriesvsArriVent BioPharma

ABT and AVBP stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.71

Value $182B

-2.55%
ABT's page

AVBP

ArriVent BioPharma, Inc.

$10.69

Value $553M

-7.53%
AVBP's page

Abbott Laboratories (ABT) has a market value of $182B and ArriVent BioPharma (AVBP) $553M. Over the last year, with dividends, ABT moved -17.8% and AVBP -48.3%. Dividend yield: ABT 2.41%, AVBP none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    AVBP$553M

    ABT is 329 times AVBP

  • Revenue, 12 months

    ABT$48.2B

    AVBP–

  • Net income, 12 months

    ABT$4.7B

    AVBP-$169M

  • Operating margin

    ABT13.8%

    AVBP–

  • ROIC

    ABT6.3%

    AVBP-45.7%

    51.9 points apart

  • P/E

    ABT38.7

    AVBP–

  • Dividend yield

    ABT2.4%

    AVBP0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-17.8%

AVBP-48.3%

50100150DecFebAprJunAugOct
Returns by period
PeriodABTWith dividendsAVBPWith dividends
1 year since November 14, 2025-17.8%Price -19.8%-48.3%Price -48.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesAVBPArriVent BioPharma

Valuation

ABTAVBP
Valuation
Price$104.71$10.69
Market value$182B$553M
Enterprise value (EV)$209B$160M
P/E38.7–
P/E, 5-year median33.7–
P/B3.61.4
EV/EBIT31.4–
Free cash flow yield3.7%–

Results and growth

ABTAVBP
Results and growth
Revenue, 12 months$48.2B–
Net income, 12 months$4.7B-$169M
Free cash flow, 12 months$6.8B–
Earnings per share, 12 months$2.69-$3.60
Revenue growth, year on year5.7%–
Revenue growth a year, past+5.1%over 5 years–
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTAVBP
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%–
Net margin9.8%–
ROIC6.3%-45.7%
ROE9.1%-49.8%

Balance sheet

ABTAVBP
Balance sheet
Cash$4.3B$393M
Total debt$31.2B$256.0K
Net debt / EBITDA3.3–
Interest cover6.7×–

Dividends and buybacks

ABTAVBP
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or AVBP

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or ArriVent BioPharma?

By market value, Abbott Laboratories ($182B) is about 329.1 times ArriVent BioPharma ($553M), at today's prices.

How did ABT and AVBP stock do over the last 1 years?

Since November 14, 2025, ABT's price moved -19.8% and AVBP's -48.3%. With dividends: ABT -17.8% (-17.8% a year), AVBP -48.3% (-48.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or AVBP?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for ArriVent BioPharma. Over the last twelve months they paid $2.52 and – per share.

Which is the better investment, Abbott Laboratories or ArriVent BioPharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.